2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease course
2021
Comparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women
Upneja A, Long JB, Aminawung JA, Kyanko KA, Kunst N, Xu X, Busch SH, Gross CP, Richman IB. Comparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women. Journal Of General Internal Medicine 2021, 37: 1870-1876. PMID: 34595682, PMCID: PMC8483166, DOI: 10.1007/s11606-021-07132-6.Peer-Reviewed Original ResearchConceptsWomen 75Older womenBreast cancerAdditional cancersSubsequent imagingWomen 67Stage ITime of diagnosisEarly-stage cancerHigh rateCancer detectionConclusionsBreast cancerPrior cancerPotential confoundersScreening outcomesHealth outcomesService beneficiariesComparative effectivenessScreening mammogramsAge groupsCancerLogistic regressionResultsOur studyWomenBreast tomosynthesis
2020
Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States
Kunst N, Alarid-Escudero F, Aas E, Coupé VMH, Schrag D, Kuntz KM. Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 2710-2718. PMID: 32998946, PMCID: PMC7747688, DOI: 10.1158/1055-9965.epi-20-0490.Peer-Reviewed Original ResearchConceptsCancer recurrence rateRecurrence rateRelative survival dataColorectal cancerSurvival dataColorectal cancer-related deathsDisease-specific survival dataStage II rectal cancerStage III colorectal cancerCancer-specific death ratesStage II colon cancerPopulation-based cancer registriesColorectal cancer interventionDiagnostic time periodsMetastatic recurrence ratesRate 6 monthsNonmetastatic colorectal cancerColorectal cancer recurrenceMonths of diagnosisAnnual recurrence rateEnd Results ProgramCancer-related deathColorectal cancer diagnosisDecision analytic modelMetastatic diseaseCost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. Patients